Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medigen Biotechnology Corp.

www.medigen.com.tw

Latest From Medigen Biotechnology Corp.

Pipeline Watch: Phase III Readouts For ADV7103, Pembrolizumab, Upadacitinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Pacts In Medtech: March/April 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, the bi-monthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. In this edition, we highlight industry pacts that were sealed in March and April 2017.

Deals Pacts in Medtech

Deal Watch: Merck Digging Into Epigenetics With Proteros Partnership

Merck could pay up to $167m to try a new epigenetic target, which would build on its existing HDAC inhibitor. Meanwhile, Celgene buys epigenetics-focused Acetylon, which will spin out new company Regenacy to work with its lead HDAC6 inhibitor outside of oncology.

Deals M & A

Shenogen’s Icaritin: A New First-Line Therapy For HCC?

Preliminary data from a Phase II study has unveiled promising results for Shenogen’s icaritin, a plant-derived product being studied as a possible therapy for hepatocellular carcinoma. The drug’s safety profile makes it particularly appealing, says the Chinese startup’s chief business officer.

BioPharmaceutical China
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
    • Generic Drugs
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Hepatic (Liver)
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Taiwan
  • Parent & Subsidiaries
  • Medigen Biotechnology Corp.
  • Senior Management
  • Stanley Chang, Chmn. & CEO
    Bill Ou, CFO
    Conrad Lai, PhD, VP, New Drug Dev.
  • Contact Info
  • Medigen Biotechnology Corp.
    Phone: (886) 2-7736-1234
    14F., No.3, Park St.
    Nangang Dist.
    Taipei, 11503
    Taiwan
Advertisement
Advertisement
UsernamePublicRestriction

Register